Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 149 IN SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 149 IN SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium is the major intracellular cation; it maintains cellular membrane potential, nerve impulse transmission, and muscle contraction. Sodium chloride provides sodium and chloride ions for extracellular fluid balance.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion: Adults, 10-20 mEq/h (as potassium) via central line; rate not to exceed 10-20 mEq/h; maximum 150 mEq/day. Concentration 0.149% provides 2 mEq K+/100 mL.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium has no classic terminal half-life as it is an electrolyte. In stable patients, the whole-body turnover half-life is approximately 30 minutes due to rapid distribution and renal clearance.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Primarily renal: approximately 90% of potassium is excreted via the kidneys, with about 10% eliminated in feces. Renal excretion is regulated by aldosterone and distal nephron secretion.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."